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Mx1, OAS1 and OAS2 
polymorphisms are associated with 
the severity of liver disease in HIV/
HCV-coinfected patients: A cross-
sectional study
Mónica García-Álvarez1, Juan Berenguer2,3, María A. Jiménez-Sousa1, Daniel Pineda-Tenor1, 
Teresa Aldámiz-Echevarria2,3, Francisco Tejerina2,3, Cristina Diez2,3, Sonia Vázquez-Morón1 & 
Salvador Resino1
The mechanisms involved in the chronic hepatitis C progression are incompletely understood. The aim 
was to analyze the association between 2′5′oligoadenylate synthetase 1,2 and 3 (OAS1-3) and myxovirus 
resistance proteins 1 (Mx1) polymorphisms and severity of liver disease in human immunodeficiency 
virus (HIV)/hepatitis C virus (HCV) coinfected patients. We performed a cross-sectional study in 219 
patients that underwent a liver biopsy. DNA genotyping for Mx1 (rs469390), OAS1 (rs2285934), OAS2 
(rs1293762) and OAS3 (rs2010604) was performed by using GoldenGate assay. The outcome variables 
ion liver biopsy were: (i) significant fibrosis (F ≥ 2); (ii) moderate activity grade (A ≥ 2). Additive model 
of inheritance for genetic association test was used. The likelihood of having significant fibrosis (F ≥ 2) 
was lower in patients carrying OAS2 rs1293762 A allele [adjusted odds ratio (aOR) = 0.51; p = 0.040]. 
Besides, the likelihood of having moderate activity grade (A ≥ 2) was higher in patients carrying Mx1 
rs464397 C allele (aOR = 1.63; p = 0.028) and Mx1 rs469390 G allele (aOR = 1.97; p = 0.005), while it 
was lower in patients carrying OAS1 rs2285934 A allele (aOR = 0.64; p = 0.039) and OAS2 rs1293762 A 
allele (aOR = 0.41; p = 0.009). In conclusion, Mx1 and OAS1-2 polymorphisms were associated with the 
severity of liver disease in HIV/HCV-coinfected patients, suggesting a significant role in the progression 
of hepatic fibrosis.
Only a minority of patients may spontaneously clear the hepatitis C virus (HCV) during the acute phase of infec-
tion, which correlates with a rapid induction of innate response, especially interferon-stimulated genes (ISGs)1. 
However, the majority of patients is unable to clear the HCV and develops chronic hepatitis C (CHC), which may 
cause irreversible fibrosis, leading to cirrhosis and hepatocellular carcinoma1,2. Moreover, CHC is accelerated in 
human immunodeficiency virus (HIV)/HCV coinfected patients, resulting in higher rates of disease progression 
than HCV mono-infected patients3.
The pathogenic mechanisms involved in this progress are incompletely understood, but it is known that the 
alternations of liver inflammatory profiles and the impaired immune responses are thought to be an important 
determinant of the rate of fibrosis progression2. Among others, chronic HCV infection has a pronounced effect on 
gene expression of a subset of ISGs such as 2′ 5′ oligoadenylate synthetase (OAS) family and myxovirus resistance 
proteins (Mx)4. The Mx1 protein is a GTPase that acts at an early step of the virus life cycle, prior to the genome 
replication, by trapping viral components and preventing them from reaching their cellular destination4. OAS 
proteins are able to synthesize 2′ ,5′ -oligomers, which specifically activate the latent form of RNaseL, which may 
then mediate RNA degradation, contributing to decay of viral RNA4. Single nucleotide polymorphisms (SNPs) 
in the OAS gene (chromosome 12) and Mx gene (chromosome 21) have been related to severity and/or outcome 
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of viral infections such as tick-borne encephalitis5, West Nile virus6, dengue virus7, coronavirus8, and hepatitis 
B9. Regarding to HCV infection, Mx1 rs2071430 polymorphism has been related to HCV clearance during acute 
HCV infection and after interferon (IFN) therapy, and higher severity of liver disease in HCV-monoinfected 
patients10–13. However, to our knowledge, there is no report related to OAS/Mx SNPs and severity of liver disease 
in HIV/HCV coinfected patients.
The aim of this study was to analyze the association between Mx1 and OAS1-3 polymorphisms and severity of 
liver disease in HIV/HCV coinfected patients.
Results
Characteristics of the study population. Table 1 shows the epidemiological and clinical characteristics 
of 219 HIV/HCV-coinfected patients at the time of liver biopsy. Regarding liver biopsy, 49.8% had significant 
fibrosis (F ≥ 2), 52.6% had moderate necroinflammatory activity (A ≥ 2), and 15.3% had alanine aminotrans-
ferase (ALT) ≥ 150 IU/L.
Mx1 and OAS1-3 polymorphisms. Table 2 shows the characteristics of SNPs, which displayed missing 
values < 5% and were in HWE (p > 0.05). When SNPs frequencies in HIV/HCV coinfected patients were com-
pared to the SNPs frequencies in healthy subjects from the IBS, we only found differences between groups for 
Mx1 rs469390 AA (p = 0.011) and Mx1 rs469390 AG (p = 0.036) genotypes.
Association between Mx1 and OAS1-3 polymorphisms and liver disease. Table 3 shows the rela-
tionship of Mx1 and OAS1-3 polymorphisms with severity of liver disease under a model of additive inheritance, 
which was the genetic model that best fitted our data. The trend of having significant fibrosis (F ≥ 2) was lower in 
patients carrying of OAS2 rs1293762 A allele (p = 0.023). The trend of having moderate activity grade (A ≥ 2) was 
higher in patients carrying Mx1 rs464397 C allele (p = 0.015) and Mx1 rs469390 G allele (p = 0.003); while it was 
lower in patients carrying OAS1 rs2285934 A allele (p = 0.026), OAS2 rs1293762 A allele (p = 0.002), and it was 
nearly significant for OAS3 rs2010604 C allele (p = 0.095). Moreover, the likelihood of having significant fibrosis 
(F ≥ 2) in liver biopsy was lower in patients carrying OAS2 rs1293762 A allele [adjusted odds ratio (aOR) = 0.51; 
p = 0.040]. Besides, the likelihood of having moderate activity grade (A ≥ 2) was higher in patients carrying Mx1 
rs464397 C allele (aOR = 1.63; p = 0.028) and Mx1 rs469390 G allele (aOR = 1.97; p = 0.005), while it was lower 
in patients carrying OAS1 rs2285934 A allele (aOR = 0.64; p = 0.039) and OAS2 rs1293762 A allele (aOR = 0.41; 
p = 0.009).
Figure 1 shows the relation between MX1 and OAS1-3 genetic polymorphisms and serum ALT. We found that 
patients carrying Mx1 rs464397 CC genotype and Mx1 rs469390 GG genotype had higher values of serum ALT 
and percentage of patients with ALT ≥ 150 IU/L. However, we did not find any significant association in multivar-
iate regression analysis (data not shown). Moreover, we also analyzed the relation between MX1 and OAS1-3 pol-
ymorphisms and serum aspartate aminotransferase (AST), but we did not find any association (data not shown).
Table 4 shows the relationship among haplotype of Mx1 gene (rs464397, rs458582, rs469390) and OAS1-3  
cluster (rs2285934, rs2285933, rs2010604, rs739903, rs1293762) and severity of liver disease. The likelihood 
of having moderate activity grade (A ≥ 2) in liver biopsy was higher in patients with Mx1 CTG haplotype 
(aOR = 1.44; p < 0.001) and lower in patients with Mx1 CTA haplotype (aOR = 0.62; p = 0.007). Moreover, the 
likelihood of having moderate activity grade (A ≥ 2) in liver biopsy was lower in patients with OAS1-3 AGCTA 
haplotype (aOR = 0.78; p = 0.008).
Discussion
To our knowledge, this study is the first description of the relationship between Mx1 and OAS1-3 polymorphisms 
and severity of liver disease in HIV/HCV-coinfected patients. The major findings of the present study were that 
Mx1 rs464397 C allele, Mx1 rs469390 G allele, and Mx1 CTG haplotype were associated with higher odds of hav-
ing moderate activity grade (A ≥ 2) in liver biopsy, while OAS1 rs2285934 A allele, OAS2 rs1293762 A allele, and 
OAS1-3 AGCTA haplotype were related to lower likelihood of having moderate activity grade (A ≥ 2). Besides, 
OAS2 rs1293762 A allele was related to lower likelihood of having significant fibrosis (F ≥ 2) in liver biopsy. 
Thus, Mx1 and OAS1-2 polymorphisms might play a role in developing of liver disease in HIV/HCV-coinfected 
patients.
In our study, we included a control group to show that our study cohort had allelic and genotypic frequencies 
similar to the general population. However, we found significant differences in allelic and genotypic frequencies 
of Mx1 rs469390 between HIV/HCV coinfected patients and Iberian populations in Spain from HapMap data. 
This observation might suggest that Mx1 rs469390 could be associated to innate resistance to HCV infection. 
However, our study design is not adequate to draw such conclusions due to a number of factors that we do not 
control. For example, our cohort may have a survival bias because patients were more than 20 years of median 
with HIV and HCV infections. In addition, patients were selected due to they were candidates for antiviral treat-
ment against HCV because progression of liver disease was suspected.
In the setting of CHC, the immune system initially attempts to eradicate the HCV, but besides, probably pro-
motes hepatocyte damage and fibrosis through direct cellular toxicity and the release of inflammatory cytokines2. 
The innate immune response against viruses produce type I IFN (alpha, beta), which induces the expression 
of Mx1 protein4,14. Although its effect against HCV is not well documented, high levels of Mx1 protein have 
been detected in IFN-treated HCV patients with sustained virological response15. In fact, Mx1 rs2071430 pol-
ymorphism, in the promoter region, has been related to Mx1 gene expression, spontaneous viral clearance 
during acute HCV infection, higher hepatic fibrosis score and hepatitis activity grade, and response to IFN 
therapy in HCV-monoinfected patients10–13. In the in silico analysis performed, we found that Mx1 rs464397 
seems to be implicated in both proximal (open chromatin region, transcription factor binding sites and histone 
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Age, years 39.8 (37.4; 44)
Epidemiological history
HIV acquired by IVDU 193 (88.1%)
Years since HCV infection 21.3 (17; 24.3)
High alcohol intake 119 (54.3%)
High alcohol intake at biopsy study 30 (13.7%)
CDC category C 60 (27.4%)
Metabolic markers
BMI, kg/m2 22.3 (20.8; 24.6)
BMI ≥ 25 kg/m2 50 (23%)
HOMA 2.10 (1.27; 3.75)
HOMA ≥ 3 71 (33.5%)
Antiretroviral therapy 
cART 183 (83.6%)
Time on cART, years 4.4 (2.5; 6.6)






Nadir CD4+ , T cells/μ L 189 (83; 315)
CD4+ , T cells/μ L 467 (324; 672)
HIV-RNA < 50 copies/mL 162 (74%)
HCV markers





HCV RNA > 500,000 UI/mL (n = 216) 161 (74.5%)







Activity grade (n = 215)




ALT (IU/L) (n = 219) 72 (45; 114)
ALT ≥ 150 IU/L 33 (15.3%)
AST (IU/L) (n = 215) 55 (37; 82)
AST ≥ 100 IU/L 33 (15.3%)
AST: ALT (n = 215) 0.79 (0.63; 0.97)
AST: ALT < 1 110 (50.2%)
Table 1. Clinical and epidemiological characteristics of HIV/HCV-coinfected patients. Values are expressed 
as absolute numbers (%) and median (percentile 25; percentile 75). Sometimes, the percentages were not 
calculated from all patients because some data was missing. Abbreviations: BMI, body mass index; HOMA, 
homeostatic model assessment; HCV, Hepatitis C virus; CDC category C, centers for disease control and 
prevention classification system, clinical category C which includes any condition listed in the CDC’s 1897 
surveillance case definition of AIDS; PI-based, protein inhibitor-based therapy; NNRTI-based, non-nucleoside 
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markers) and distal regulation. Furthermore, rs464397 seems also be involved in RNA binding protein-mediated 
post-transcriptional regulation as well as to be a SNP with experimental expression quantitative trait loci (eQTL) 
evidence. On the other hand, Mx1 rs469390 polymorphism is a missense variant (V379I) that might not affect 
protein structure; but it seems influence an exonic splicing enhancer motif and it might be involved in protein 
domain abolishing. In this way, MX1 rs469390 polymorphism could decrease expression of MX1, getting worse 
the control of HCV, and might therefore be related to the increase of sustained inflammation and progression of 
liver disease.
The OAS proteins play an important role in the innate immune response and genetic variants in the OAS 
genes are known to affect OAS activity and are associated with outcome of viral infections16. The OAS1 rs2660, 
rs10774671, and rs3741981 polymorphisms have been related to persistent HCV infection11,17 and progression 
of HCV disease18; and OAS1 polymorphism at exon 7 splice acceptor site with response to IFN therapy in HCV 
infected patients19. The OAS2 polymorphism rs1293762 has been associated with predisposition to CHC20. In our 
study, OAS1-3 polymorphisms were related to lower likelihood of having significant liver disease (A ≥ 2 and/or 
F ≥ 2), indicating that the A-allele conferred a protective effect with respect to liver disease progression. OAS1 
rs2285934 and OAS2 rs1293762 polymorphisms are located in intron 3 and intron 2, respectively. In the in silico 
analysis, both SNPs seem to be involved in RNA binding protein-mediated post-transcriptional gene regulation. 
In this way, OAS1 rs2285934 and OAS2 rs1293762 polymorphisms could increase expression of OAS1 and OAS2, 
improving the control of HCV, and might therefore be related to the decrease of sustained inflammation and 
progression of liver disease.
As discussed above, the presence of Mx1 and OAS1-3 polymorphisms may be related to have moderate or 
significant liver disease. This association that we observed might be due to the proximity to other SNPs that may 
modulate Mx1 gene expression, or a direct effect of Mx1 and OAS1-3 polymorphisms analyzed in this study. On 
the one hand, haplotype analysis showed a stronger association with liver disease than that found with each pol-
ymorphism alone. On the other hand, the in silico analysis showed that polymorphisms alone could have some 
influence on the expression of the proteins involved. However, it would be necessary to demonstrate if these Mx1 
and OAS1-3 polymorphisms may modify the expression of Mx1 and OAS1-3 genes.
The impact of OAS/MX1 SNPs on fibrosis progression in CHC has not been picked up in the GWAS previously 
carried out21,22. However, we found a relatively strong association between OAS/MX1 SNPs and the severity of 
liver disease in our HIV/HCV coinfected patients. This could be because: (a) GWAS usually does not have the 
power to detect all, only the biggest effects. Besides, note that strong statistical adjustments on the p-value are 
carried out for correcting multiple testing; (b) we studied a SNP candidate with MAF greater than 20%. In these 
cases, an individual effect is more easily detected when the size of sample is small23; (c) we should not discard the 
effect of HIV infection on the immune system, which could show the influence of OAS/MX1 polymorphisms on 
CHC progression.
Finally, several aspects have to be taken into account for the correct interpretation of the results. Firstly, this is a 
cross-sectional study with a limited number of patients, which could limit achieving statistically significant values. 
Besides, the cross-sectional design nature of the analyses may be a confounding factor. Secondly, data were col-
lected retrospectively, which entails a lack of uniformity. Thirdly, all selected patients met a set of criteria for start-
ing HCV treatment (e.g., no alcohol abuse, high CD4 cell counts, controlled HIV replication, and good treatment 
adherence), and this may have introduced a selection bias. Fourthly, regarding the statistical significance, there 
is a considerable controversy about adjusting the “p-value” after multiple tests on clinical-orientated studies24,25. 
In our study, there was a hypothesis supported by theory and previous reports that related Mx1 and OAS1-3 pol-
ymorphisms to severity and/or outcome of viral infections5–9, including HCV infection10–13. Therefore, we were 
not literally doing a random search of a meaningful result, and our results should not be affected by the fact of car-
rying out a high number of statistical tests. Fifthly, this study was performed on patients with European ancestry, 
and it would be interesting to perform these analyses on different ethnic groups. Finally, our study only included 
HIV/HCV-coinfected patients and it would be interesting to know the role of studied polymorphisms in HCV 
monoinfected patients, but we did not have access to a cohort of HCV monoinfected patients.
In conclusion, Mx1 and OAS1-2 polymorphisms were associated with the severity of liver disease in patients 
coinfected with HIV and HCV, suggesting that these polymorphisms might play a significant role in the pro-
gression of hepatic fibrosis. Further analysis involving large numbers of patients are needed to corroborate these 
associations that we have found.
Materials and Methods
Study population. We performed a cross-sectional study in 219 HIV/HCV-coinfected patients that under-
went a liver biopsy between September 2000 and November 2008. The study was conducted in accordance with 
the Declaration of Helsinki and patients gave their written consent for the study. The Institutional Review Board 
and the Research Ethic Committee of the Instituto de Salud Carlos III approved the study. Each participating 
patient signed an informed consent form.
Liver biopsies were performed on patients who were potential candidates for anti-HCV therapy and had not 
received previous IFN therapy (naïve for HCV-treatment). Selection criteria were: no clinical evidence of hepatic 
decompensation, detectable HCV RNA by polymerase chain reaction (PCR), negative hepatitis B surface antigen, 
availability of DNA sample, CD4 + lymphocyte count higher than 200 cells/μ L, and stable combination antiret-
roviral therapy (cART) for at least 6 months before study entry or no need for cART according to treatment 
reverse transcriptase inhibitor -based therapy; 3NRTI-based, triple nucleoside regimen; HIV; Human 
immunodeficiency virus; HIV-RNA, HIV plasma viral load; HCV-RNA, HCV plasma viral load; ALT, alanine 
aminotransferase; AST Aspartate Aminotransferase.
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guidelines used in the study period26,27. Patients with active opportunistic infections, active drug addiction, and 
other concomitant severe diseases were excluded. All subjects included in our study were European white.
Epidemiological and clinical data. Clinical and epidemiological data were obtained from medical 
records. The duration of HCV infection for patients with a history of intravenous drug use was estimated start-




(n = 219) IBS group (n = 107) χ2 test(a) χ2 test (b)
p-value Alleles Genotype Alleles Genotype p-value p-value
Mx1 rs464397
0.420 C 53% CC 26% C 53% CC 28% 0.906 0.802
T 47% CT 53% T 47% CT 50% 0.695
TT 21% TT 22% 0.949
Mx1 rs469390
0.410 A 56% AA 30% A 64% AA 45% 0.208 0.011
G 44% AG 52% G 35% AG 39% 0.036
— — GG 17% — — GG 16% 0.945
OAS1 rs2285934
0.450 C 66% CC 45% C 67% CC 41% 0.956 0.572
A 34% CA 42% A 33% CA 51% 0.157
— — AA 13% — — AA 8% 0.250
OAS2 rs1293762
0.790 C 54% CC 29% C 52% CC 25% 0.824 0.531
A 46% CA 49% A 48% CA 54% 0.465
— — AA 22% — — AA 21% 0.950
OAS3 rs2010604
0.360 G 67% GG 46% G 66% GG 42% 0.955 0.573
C 33% GC 41% C 33% GC 49% 0.212
— — CC 12% — — CC 8% 0.364
Table 2. Summary of Hardy Weinberg Equilibrium and frequencies of alleles and genotypes for Mx1 
and OAS1-3 polymorphisms in HIV/HCV coinfected patients compared to Iberian populations in Spain 
from HapMap data (http://www.ncbi.nlm.nih.gov/bioproject/59819). Statistically significant differences are 
shown in bold. P-values were calculated by Chi-squared test; (a), differences between allele frequencies; (b), 
differences between genotype frequencies. Abbreviations: HWE, Hardy Weinberg Equilibrium; HIV, human 
immunodeficiency virus; HCV, hepatitis C virus; IBS, Iberian populations in Spain; OAS, 2′ 5′ oligoadenylate 
synthetase; Mx1, myxovirus resistance proteins.
SNPs Unadjusted Adjusted
Mx1 rs464397 TT CT CC P(a) aOR (95%CI) p(b)
F ≥ 2 42.2% (19/45) 50.0% (58/116) 55.2% (32/58) 0.198 1.15 (0.75; 1.77) 0.501
A ≥ 2 38.6% (17/44) 52.6% (60/114) 63.2% (36/57) 0.015 1.63 (1.05; 2.52) 0.028
Mx1 rs469390 AA AG GG P(a) aOR (95%CI) p(b)
F ≥ 2 39.4% (26/66) 53.5% (61/114) 55.3% (21/38) 0.077 1.22 (0.80; 1.88) 0.347
A ≥ 2 40% (25/65) 53.6% (60/112) 70.3% (26/37) 0.003 1.97 (1.23; 3.16) 0.005
OAS1 rs2285934 CC AC AA P(a) aOR (95%CI) p(b)
F ≥ 2 52.0% (51/98) 49.5% (46/93) 42.9% (12/28) 0.415 0.88 (0.58; 1.33) 0.539
A ≥ 2 60.4% (58/96) 48.4% (44/91) 39.3% (11/28) 0.026 0.64 (0.42; 0.98) 0.039
OAS2 rs1293762 CC AC AA P(a) aOR (95%CI) p(b)
F ≥ 2 60.9% (39/64) 47.7% (51/107) 39.6% (19/48) 0.023 0.51 (0.26; 0.97) 0.040
A ≥ 2 66.7% (42/63) 51.0% (53/104) 37.5% (18/48) 0.002 0.41 (0.21; 0.80) 0.009
OAS3 rs2010604 GG CG CC P(a) aOR (95%CI) p(b)
F ≥ 2 52.5% (53/101) 48.9% (44/90) 44.4% (12/27) 0.431 0.91 (0.59; 1.38) 0.651
A ≥ 2 59% (59/100) 48.3% (42/87) 44.4% (12/27) 0.095 0.74 (0.48; 1.13) 0.169
Table 3. Summary of the differences of genotypic frequencies (Mx1 rs464397, MX1 rs469390, OAS1 
rs2285934, OAS2 rs1293762 and OAS3 rs2010604) in relation to severity of liver disease and the adjusted 
logistic regression analysis for the polymorphisms in HIV/HCV coinfected patients. Statistically significant 
differences are shown in bold. (a)P-values were calculated by Chi-squared test for trend (linear by linear 
association); (b)P-values were calculated by multivariate logistic regression adjusted by the most important 
clinical and epidemiological characteristics (see statistical analysis section). Sometimes, the percentages were 
not calculated from all patients because some data was missing. Abbreviations: 95%CI, 95% of confidence 
interval; aOR, adjusted odds ratio; p-value, level of significance; A ≥ 2, moderate activity (Metavir); F ≥ 2, 
significant fibrosis (Metavir); OAS, 2′ 5′ oligoadenylate synthetase; Mx1, myxovirus resistance proteins.
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Figure 1. Summary of the differences of serum ALT according to genotypes of Mx1 rs464397, MX1 
rs469390, OAS1 rs2285934, OAS2 rs1293762 and OAS3 rs2010604 in HIV/HCV coinfected patients. 
P-values were calculated by Student’s t-test and Chi-squared test. Abbreviations: OAS, 2′ 5′ oligoadenylate 
synthetase; Mx1, myxovirus resistance proteins.
www.nature.com/scientificreports/
7Scientific RepoRts | 7:41516 | DOI: 10.1038/srep41516
practices for HCV transmission28. The duration of HCV infection was not calculated when the date of initiation 
of their HCV infection could not be determined with certainty. Consumption of more than 50 g of alcohol per 
day for at least 12 months was considered as a high intake. Body mass index (BMI) was calculated as the weight 
in kilograms divided by the square of the height in meters.
Biochemistry panel was measured using an autoanalyzer Hitachi 912 (Boehringer Mannheim, Germany), 
while patients were fasting. The degree of insulin resistance was estimated for each patient using the homeostatic 
model assessment (HOMA)29: fasting plasma glucose (mmol/L) times fasting serum insulin (mU/L) divided by 
22.5.
HCV assays. HCV infection was documented in all patients by enzyme-linked immunosorbent assay and 
PCR test. HCV genotype was determined by hybridization of biotin-labeled PCR products to oligonucleotide 
probes bound to nitrocellulose membrane strips (INNO-LiPA HCV II, Innogenetics, Ghent, Belgium). Plasma 
HCV-RNA viral load was measured by PCR (Cobas Amplicor HCV Monitor Test, Branchburg, NJ, USA) and 
real-time PCR (COBAS AmpliPrep/COBAS TaqMan HCV test); and results were reported in terms of interna-
tional units per milliliter (IU/mL). The limit of detection varied between 10 IU/mL and 600 IU/mL depending 
on the HCV diagnostic test used at the time of biopsy. There was no patient with HCV viral loads below the limit 
of detection. The HCV RNA level of 500,000 UI/ml was chosen as cutoff for low vs. high viral load (circulating 
HCV RNA)30,31.
Liver biopsy. Liver biopsies were performed as we described previously32. The samples were always evaluated 
by the same pathologist, who was unaware of the patients’ clinical or laboratory data. Liver fibrosis and necroin-
flammatory activity were estimated according to Metavir score as follows33: F0, no fibrosis; F1, mild fibrosis; F2, 
significant fibrosis; F3, advanced fibrosis; and F4, definite cirrhosis. The degree of necroinflammation (activity 
grade) was scored as follows: A0, no activity; A1, mild activity; A2, moderate activity; A3, severe activity.
Genotyping of DNA polymorphisms. The most common SNPs in Mx1 gene (chromosome 21) and 
OAS1-3 genes (chromosome 12) were selected using the databases of HapMap Project (http://snp.cshl.org/
cgi-perl/gbrowse/hapmap_B35/) and NCBI (dbSNP) (http://www.ncbi.nlm.nih.gov/entrez/). The selection crite-
ria were: (i) SNPs located in putative regulatory regions, or splicing control elements (SCE), or missense variants; 
(ii) minor allelic frequency (MAF) greater than 20% in European people in order to have guarantees to obtain 
significant associations when working with small sample sizes34. With this setting, we found three SNPs in Mx1 
gene (rs464397 in intron 3, rs458582 in intron 5, and rs469390 in exon 13 (missense)) and other five SNPs at OAS 
genes (OAS1 rs2285934 in intron 3, OAS2 rs1293762 in intron 2, OAS3 rs739903 in 3′ UTR, OAS3 rs2285933 
in exon 6 (missense), and OAS3 rs2010604 in 3′ UTR). Finally, five polymorphisms were selected as tagSNPs 
according to linkage disequilibrium (LD) (Fig. 2): two SNPs at Mx1 (rs464397 and rs469390) and three SNPs at 
OAS (OAS1 rs2285934, OAS2 rs1293762, and OAS3 rs739903). Three SNPs (Mx1 rs458582, OAS3 rs2285933, 
and OAS3 rs2010604) were discarded for the analysis of individual association because these SNPs were at high 
linkage disequilibrium (LD) (Fig. 2).
Genomic DNA was extracted from peripheral blood with Qiagen kit (QIAamp DNA Blood Midi/Maxi; 
Qiagen, Hilden, Germany). DNA samples were sent at the Spanish National Genotyping Center (CeGen; http://
www.cegen.org/) for DNA genotyping by using GoldenGate assay with VeraCode Technology (Illumina Inc., San 
Diego, California, USA).
F ≥ 2 A ≥ 2
Freq. aOR (95% CI) p aOR (95% CI) p
Mx1 haplotypes
rs464397 rs458582 rs469390
C T G 0.377 1.44 (0.92–2.26) 0.109 2.38 (1.45–3.91) <0.001
T G A 0.413 0.85 (0.54–1.34) 0.487 0.68 (0.42–1.09) 0.104
C T A 0.141 0.62 (0.32–1.22) 0.165 0.39 (0.19–0.79) 0.007
OAS1-3 haplotypes
rs2285934 rs2285933 rs2010604 rs739903 rs1293762
A G C T A 0.281 0.78 (0.50–1.21) 0.261 0.55 (0.35–0.87) 0.008
C G G T A 0.133 0.66 (0.34–1.25) 0.195 0.93 (0.50–1.76) 0.836
C C G C C 0.239 1.14 (0.70–1.84) 0.592 1.40 (0.85–2.29) 0.181
C G G T C 0.250 1.33 (0.82–2.16) 0.250 1.45 (0.88–2.39) 0.140
Table 4. Association of haplotype of Mx1 gene and OAS1-3 cluster with severity of liver disease in HIV/
HCV coinfected patients. Statistically significant differences are shown in bold. P-values were calculated by 
multivariate logistic regression adjusted by the most important clinical and epidemiological characteristics (see 
statistical analysis section). Haplotypes with frequencies less than 5% have not included. Abbreviations: aOR, 
adjusted odds ratio; 95%CI, 95% of confidence interval; p-value, level of significance; A ≥ 2, moderate activity 
(Metavir); F ≥ 2, significant fibrosis (Metavir); OAS, 2′ 5′ oligoadenylate synthetase; Mx1, myxovirus resistance 
proteins.
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Moreover, for healthy subjects, the frequencies of alleles and genotypes for studied polymorphisms were 
obtained using the 1000 Genomes Project website (http://www.1000genomes.org/home), which provide a broad 
representation of common human genetic variation by applying whole-genome sequencing to a diverse set 
of individuals from multiple populations35. We select the IBS (Iberian populations in Spain) population that 
included 107 individuals.
Outcome variables. The primary outcome variables were related to severity of liver disease: significant 
fibrosis (F ≥ 2) and moderate activity grade (A ≥ 2). These outcomes were developed after a minimum follow-up 
time of 10 years with HCV infection.
Statistical analysis. Chi-square test, Chi-square test for trend (linear by linear association), Student’s t-test, 
and multivariate logistic regression analysis were used to investigate the relationship among Mx1 and OAS pol-
ymorphisms and severe liver disease. We included the SNP with the Enter algorithm (Forced Entry) and the 
covariables with the Stepwise algorithm (at each step, factors are considered for removal or entry: a p-value 
for entry and exit of 0.15 and 0.20, respectively). Thus, each logistic regression test was only adjusted by the 
most significant co-variables associated with each one of the outcome variables, avoiding the over-fitting of the 
regression. The covariables used were gender, age, alcohol intake at biopsy study, BMI, HOMA, nadir CD4+ 
T-cells, AIDS, undetectable HIV-RNA (< 50 copies/ml), CD4+ T-cells, time on cART, type of cART, HCV-RNA 
≥ 500,000 IU/ml, time of HCV infection, and HCV genotype. Besides, we also used data of the PNPLA3 rs738409 
polymorphism and the IL28B rs12980275 polymorphism, which have already been published by us and showed 
significant association with liver fibrosis in HIV/HCV coinfected patients36,37. The genetic association study was 
carried out according to the genetic model that best fit our data (additive, recessive, dominant, codominant, and 
overdominant). These analyses were tested according to the goodness of fit evaluated by Akaike information cri-
terion (AIC) value and Bayesian information criterion (BIC). These analyses were performed by using the IBM 
SPSS Statistics for Windows, Version 21.0 (IBM Corp, Chicago, Armonk, NY, USA).
Hardy-Weinberg equilibrium (HWE) for all SNPs was assessed by a Chi-square test, considering equilib-
rium when p > 0.05. In addition, pair-wise linkage disequilibrium (LD) analysis was computed to detect the 
inter-marker relationship using the standardized D′ and r2 values by Haploview 4.2 software. Haplotype-based 
association testing was performed using Plink software (http://pngu.mgh.harvard.edu/~purcell/plink/) compar-
ing each haplotype with the rest of haplotypes (there was no reference category). All p-values were two-tailed and 
statistical significance was defined as p < 0.05.
Figure 2. Pairwise linkage disequilibrium (LD) patterns for genetic polymorphisms of MX1 and OAS1-3. 
Each diagonal represents a different SNP, with each square representing a pairwise comparison between two 
SNPs. Abbreviations: OAS, 2′ 5′ oligoadenylate synthetase; Mx1, myxovirus resistance proteins.
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The in silico analysis for possible functional implication of each polymorphism was evaluated by using two 
web-tools: a) VarioWatch (http://genepipe.ncgm.sinica.edu.tw/variowatch/); b) rSNABase (http://rsnp.psych.
ac.cn/).
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